SOUTH JORDAN, Utah, April 07, 2025 (GLOBE NEWSWIRE) -- Merit Medical Systems, Inc. (NASDAQ: MMSI), a leading global manufacturer and marketer of healthcare technology, announced today that it will release its financial results for the quarter ended March 31, 2025, after the close of the stock market on Thursday, April 24, 2025. Merit plans to hold its investor conference call on the same day (Thursday, April 24, 2025) at 5:00 p.m. Eastern (4:00 p.m. Central, 3:00 p.m. Mountain, and 2:00 p.m. Pacific).
To access the conference call, please pre-register using the following link. Registrants will receive confirmation with dial-in details.
A live webcast and slide deck can be accessed using this link. A link to both register for the conference call and view the webcast will be made available at www.merit.com.
ABOUT MERIT
Founded in 1987, Merit Medical Systems, Inc. is engaged in the development, manufacture, and distribution of proprietary medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy. Merit serves customers worldwide with a domestic and international sales force and clinical support team totaling more than 800 individuals. Merit employs approximately 7,300 people worldwide.
| Contacts: | |
| PR/Media Inquiries: Sarah Comstock Merit Medical +1-801-432-2864 This email address is being protected from spambots. You need JavaScript enabled to view it. | Investor Inquiries: Mike Piccinino, CFA, IRC ICR Healthcare +1-443-213-0509 This email address is being protected from spambots. You need JavaScript enabled to view it. |
| Last Trade: | US$90.57 |
| Daily Change: | -1.39 -1.51 |
| Daily Volume: | 566,432 |
| Market Cap: | US$5.280B |
April 09, 2025 March 27, 2025 March 25, 2025 March 10, 2025 February 25, 2025 | |
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
